Skip to main content
. 2021 Feb 4;39(11):1223–1233. doi: 10.1200/JCO.20.01659

FIG 2.

FIG 2.

(A) Probability of overall survival after allogeneic transplantation in the EuroMDS cohort. Patients were stratified according to specific genomic features. A total of 424 cases with complete information about transplant procedures and clinical outcome entered the analysis. (B) Comparison of probability of survival among different genomic-based MDS groups (P values of log-rank test were reported). AML, acute myeloid leukemia; MDS, myelodysplastic syndromes.